Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology

Axonics Modulation Technologies Inc., developer of the first rechargeable implantable Sacral Neuromodulation System (SNM) for the treatment of urinary and fecal dysfunction, has been granted a new U.S. patent relating to its implantable neuromodulation technology for the treatment of urinary and fecal dysfunction.
 
U.S. Patent No. 9,427,574 relates to helical anchoring devices with a plurality of tines that engage tissue to inhibit migration of an implanted lead of a neuromodulation system.
 
“The issuance of this grant in less than eight months after filing with the USPTO [U.S. Patent and Trademark Office] underscores the novelty of the design of our tined lead for use with the Axonics SNM System and further demonstrates our commitment to developing a robust patent portfolio in support of our innovations,” said Raymond W. Cohen, Axonics CEO. “With this new U.S. patent, we now have 61 issued and 85 pending patent applications in our portfolio in various jurisdictions around the world.”
 
The Axonics patent portfolio represents technology developed under license from the Alfred Mann Foundation and technology internally developed by Axonics.

The Axonics SNM System received CE Mark approval in June 2016. The company is currently executing a post-market clinical study in select centers in the Netherlands, Belgium, France and the United Kingdom.
 
The Axonics neuromodulation platform includes, among other innovations, a miniaturized rechargeable implantable neuromodulation stimulator (IPG) that is approximately one-fourth the size of smallest currently marketed rechargeable IPGs and can be directed toward numerous clinical applications. The Axonics IPG is qualified to last at least 15 years in the body and needs to be recharged only once a week for approximately one hour via a charging system designed to optimize ease of use and patient comfort. In addition, the Axonics’ platform features a key-fob sized patient-friendly remote control and an intuitive clinician programmer that will guide and support physician implanters throughout the clinical procedure, from lead placement to programming. Axonics’ initial clinical application for its technology is Sacral Neuromodulation for the treatment of urinary and fecal dysfunction which affects more than 100 million adults in the United States and Europe. SNM therapy is an effective and durable treatment that has been widely used in Europe and the United States for the past two decades with more than 200,000 patients having benefited from the therapy to date.
 
Axonics, based in Irvine, Calif., is a privately held company developing novel implantable neuromodulation technology directed toward a number of clinical indications. Investors include Edmond de Rothschild Investment Partners, Advent Life Sciences, NeoMed Management, Legend Capital, Cormorant Asset Management and The Alfred E. Mann Foundation.